1. Home
  2. RMMZ vs ANIX Comparison

RMMZ vs ANIX Comparison

Compare RMMZ & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RiverNorth Managed Duration Municipal Income Fund II Inc.

RMMZ

RiverNorth Managed Duration Municipal Income Fund II Inc.

HOLD

Current Price

$14.95

Market Cap

123.3M

Sector

Finance

ML Signal

HOLD

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$2.97

Market Cap

102.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMMZ
ANIX
Founded
N/A
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
123.3M
102.6M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
RMMZ
ANIX
Price
$14.95
$2.97
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.67
AVG Volume (30 Days)
15.8K
113.0K
Earning Date
01-01-0001
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.82
EPS
N/A
N/A
Revenue
N/A
$210,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.83
$2.44
52 Week High
$15.29
$5.46

Technical Indicators

Market Signals
Indicator
RMMZ
ANIX
Relative Strength Index (RSI) 61.01 51.78
Support Level $14.62 $2.74
Resistance Level $15.11 $3.11
Average True Range (ATR) 0.14 0.18
MACD 0.02 -0.01
Stochastic Oscillator 75.44 36.88

Price Performance

Historical Comparison
RMMZ
ANIX

About RMMZ RiverNorth Managed Duration Municipal Income Fund II Inc.

RiverNorth Managed Duration Municipal Income Fund II Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Share on Social Networks: